Bioinvent International AB;Cancer Research Technology Limited
发明人:
FRENDÉUS, Björn,MÅRTENSSON, Linda,SEMMRICH, Monika,TEIGE, Ingrid,BEERS, Stephen,AL-SHAMKHANI, Aymen,GRAY, Juliet,GLENNIE, Martin
申请号：
AU2018305209
公开号：
AU2018305209A1
申请日:
2018.07.26
申请国别(地区):
AU
年份:
2020
代理人:
摘要：
Described is the sequential administration of first a Treg depleting antibody mole- cute selected from antibody molecules, such as an antibody molecule binding specifically to target belonging to the tumour necrosis factor receptor superfamily (TNFRSF), such as a Treg depleting anti-4-1 BB antibody or a Treg depleting OX-40 antibody, and then an immunostimulatory antibody molecule, such as an immunostimulatory anti-4-1 BB anti- body or an immunostimulatory OX-40 antibody, for use in the treatment of cancer. De- scribed are also novel anti-4-1 BB antibodies and novel OX-40 antibodies that may be used in such sequential administration.
